靶向铁死亡:中药化合物治疗呼吸系统疾病的研究综述
本综述系统梳理铁死亡在慢性阻塞性肺疾病、急性肺损伤、支气管哮喘、肺纤维化和肺癌等呼吸系统疾病发生发展中的调控作用,并总结中药化合物通过调节system Xc- -GSH-GPX4、NCOA4介导的铁蛋白自噬、Nrf2-GPX4和Nrf2/HO-1等通路干预铁死亡的治疗潜力。目前证据主要来自动物和细胞研究,尚需高质量临床数据验证。
要点
- 铁死亡与多种呼吸系统疾病的发生发展密切相关。
- 中药化合物可调控多条铁死亡相关信号通路发挥治疗作用。
- 现有证据限于动物和细胞研究,需高质量临床验证。
核心结论
- 中药化合物通过调控铁死亡在改善呼吸系统疾病方面显示出良好潜力。
- 识别特异性的中药铁死亡诱导剂和抑制剂对开发更有效策略具有重要意义。
研究设计与样本
- 本综述检索PubMed、Web of Science、Scopus和CNKI数据库,检索词包括ferroptosis、respiratory diseases、chronic obstructive pulmonary disease、bronchial asthma、acute lung injury、pulmonary fibrosis、lung cancer、traditional Chinese medicine、traditional Chinese medicine compound、monomer和natural product,检索中药化合物靶向铁死亡治疗呼吸系统疾病的研究,数据遵循PRISMA标准。
主要发现
- 铁死亡与慢性阻塞性肺疾病、急性肺损伤、支气管哮喘、肺纤维化和肺癌的发生发展密切相关。
- 中药化合物通过调节system Xc- -GSH-GPX4、NCOA4介导的铁蛋白自噬、Nrf2-GPX4和Nrf2/HO-1等通路调控铁死亡,对呼吸系统疾病发挥治疗作用。
- 中药化合物源自天然并具有临床有效性,在治疗呼吸系统疾病方面具有独特优势。
临床怎么用
- 关注中药化合物靶向铁死亡通路作为呼吸系统疾病潜在治疗策略。
- 临床应用前需注意现有证据主要来自动物和细胞研究,尚缺乏高质量临床数据支持。
局限性
- 当前研究局限于动物和细胞研究,需高质量临床数据进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory diseases pose a grave threat to human life. Therefore, understanding their pathogenesis and therapeutic strategy is important. Ferroptosis is a novel type of iron-dependent programmed cell death, distinct from apoptosis, necroptosis, and autophagy, characterised by iron, reactive oxygen species, and lipid peroxide accumulation, as well as glutathione (GSH) depletion and GSH peroxidase 4 (GPX4) inactivation. A close association between ferroptosis and the onset and progression of respiratory diseases, including chronic obstructive pulmonary disease, acute lung injury, bronchial asthma, pulmonary fibrosis, and lung cancer, has been reported. Recent studies have shown that traditional Chinese medicine (TCM) compounds exhibit unique advantages in the treatment of respiratory diseases owing to their natural properties and potential efficacy. These compounds can effectively regulate ferroptosis by modulating several key signalling pathways such as system Xc- -GSH-GPX4, NCOA4-mediated ferritinophagy, Nrf2-GPX4, and Nrf2/HO-1, thus playing a positive role in improving respiratory diseases. PURPOSE: This comprehensive review systematically outlines the regulatory role of ferroptosis in the onset and progression of respiratory diseases and provides evidence for treating respiratory diseases by targeting ferroptosis with TCM compounds. These insights aim to offer potential remedies for the clinical prevention and treatment of respiratory diseases. STUDY DESIGN AND METHODS: We searched scientific databases PubMed, Web of Science, Scopus, and CNKI using keywords such as "ferroptosis","respiratory diseases","chronic obstructive pulmonary disease","bronchial asthma","acute lung injury","pulmonary fibrosis","lung cancer","traditional Chinese medicine","traditional Chinese medicine compound","monomer", and "natural product" to retrieve studies on the therapeutic potential of TCM compounds in ameliorating respiratory diseases by targeting ferroptosis. The retrieved data followed PRISMA criteria (preferred reporting items for systematic review). RESULTS: TCM compounds possess unique advantages in treating respiratory diseases, stemming from their natural origins and proven clinical effectiveness. TCM compounds can exert therapeutic effects on respiratory diseases by regulating ferroptosis, which mainly involves modulation of pathways such as system Xc- -GSH-GPX4,NCOA4-mediated ferritinophagy, Nrf2-GPX4, and Nrf2/HO-1. CONCLUSION: TCM compounds have demonstrated promising potential in improving respiratory diseases through the regulation of ferroptosis. The identification of specific TCM-related inducers and inhibitors of ferroptosis holds great significance in developing more effective strategies. However, current research remains confined to animal and cellular studies, emphasizing the imperative for further verifications through high-quality clinical data.
引用
- Xu M, Zhang D, Yan J, et al. Targeting ferroptosis using Chinese herbal compounds to treat respiratory diseases. Phytomedicine. 2024. PMID: 38824825. doi:10.1016/j.phymed.2024.155738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。